A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Public ClinicalTrials.gov record NCT04576156. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.
Study identification
- NCT ID
- NCT04576156
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 327 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 11, 2021
- Primary completion
- Jun 29, 2028
- Completion
- Jun 29, 2028
- Last update posted
- Jul 7, 2026
2021 – 2028
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California-San Diego/Moores UCSD Cancer Center | La Jolla | California | 92093-1503 | — |
| UCLA David Geffen School of Medicine | Los Angeles | California | 90096 | — |
| Smilow Cancer Center at YNHH | New Haven | Connecticut | 06511 | — |
| BRCR Medical Center Inc | Plantation | Florida | 33326 | — |
| University of South Florida | Tampa | Florida | 33612 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40207 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Prairie Lakes Health Care System, Inc. | Watertown | South Dakota | 57201 | — |
| The University of Texas MD | Houston | Texas | 77030-4000 | — |
| Northwest Medical Specialties PLLC | Seattle | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 132 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04576156, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 7, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04576156 live on ClinicalTrials.gov.